Royal Cornwall Hospital to help in breast cancer study
A Westcountry hospital is taking part in an international study to test a new drug said to improve survival rates by a third in breast cancer.
Doctors at the Royal Cornwall Hospital, Trelikse, Truro (RCHT) are trialling pertuzumab, made by Swiss pharmaceutical company Roche.
It is designed to help HER2-positive breast cancer patients which accounts for 25% of the disease.
If the European Medicines Agency give approval it will go on the market in March.
Buy one get one free on main course and specials excludes fillet steaks and beef wellingtons
Must book to qualify and present voucher on arrival 01209860332
Contact: 01209 700617
Valid until: Wednesday, December 11 2013
Data released today showed patients taking a combination of pertuzumab and the drug trastuzumab – also made by Roche – and chemotherapy survived longer.
Dr Duncan Wheatley, Clinical Oncologist,(RCHT) said: "These data are particularly exciting because it is rare to see a treatment that gives a meaningful survival benefit to advanced HER2-positive breast cancer patients, without significantly increasing the side effects associated with the current standard of care.
"This will translate into a longer life for patients and if approved, the treatment will likely be the new gold standard in advanced HER2-positive breast cancer."